From: A review of new hormonal therapies for prostate cancer in black men: is there enough data?
Trial (NCT) | Population | Comparison | Primary Outcomes | Secondary Outcomes | Results | Adverse Events |
---|---|---|---|---|---|---|
Tsao et al. 2016 | mCRPC black men | – | Antitumor activity (defined by a 30% decline in PSA level) | – | 90% antitumor activity | No patients discontinuing treatment because of AE Higher common AE |
Ryan et al. 2018 | M0 CRPC black men | mCRPC white men | Rate of 50% PSA decline | Time to PSA and to Rx progression | Primary: No data Secondary: No difference | NR |
Ramalingam et al. 2017 [14] | mCRPC black men | mCRPC white men (2 W:1B) | Rate of 90, 50 and 30% PSA decline | Time on therapy, time to PSA progression, OS | Primary: 90% PSA did not differ between B and W, but 50 and 30% decline were significantly higher among B Secondary: time on therapy, time to PSA progression and OS did not differ between B and W | NR |
Leuva et al. 2019 [15] | mCRPC black men | mCRPC white men | Overall survival | Efficacy of treatment using tumor growth and regression, were calculated using serial PSA values | B Patients treated with Abi only or with Abi first showed superior survival than W patients: 25.4 months vs. 22.4 months (p = 0.02) Abi efficacy was 60% higher in B than in W patients (p = 0.02) No difference between B and W patients treated with Enza | NR |